Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01041 ...
Drug Name Thalidomide
Molecular Weight 258.2295
Molecular Formula C13H10N2O4
CAS Number 50-35-1
SMILES O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12
External Links
DRUGBANK DB01041
T3DB T3D3539
PubChem Compound 5426
PDR 1705
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 0.33 - 0.33 - HANSCH,C ET AL. (1995)
Melting Point 270.0 ℃ 270 ℃ PhysProp
Water Solubility 545.0 mg/L 545 mg/L BUDAVARI,S ET AL. 1996)

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Reference
C Max 2000.0 ng/ml 2.0±0.6 mcg/ml Oral single dose; Male, men; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 4.3 h 2.9-5.7 h PO, oral; normal,healthy; leprosy; DRUGBANK
T Max 3.2 h 3.2±1.4 h Oral single dose; Male, men; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 0.13 L/h/kg 2.2±0.4 ml/min/kg PO, oral; normal,healthy; Male, men; The Pharmacological Basis of Therapeutics
Clearance 0.20 L/h/kg 3.4 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 1.1 L/kg 1.1±0.3 L/kg PO, oral; normal,healthy; Male, men; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.95 L/kg 0.95 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 6.0 h ~5-7 h elimination half-life; Single dose; DRUGBANK
Half-life 6.2 h 6.2±2.6 h PO, oral; The Pharmacological Basis of Therapeutics
Half-life 4.7 h 4.7 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 550.0 mg/kg 0.4-0.7 g/kg Optical rotation R; DRUGBANK
Toxicity LD50 1000.0 mg/kg 0.5-1.5 g/kg Optical rotation S; DRUGBANK
Toxicity LD50 550.0 mg/kg 0.4-0.7 g/kg Optical rotation R; T3DB
Toxicity LD50 1000.0 mg/kg 0.5-1.5 g/kg Optical rotation S; T3DB
Eliminate Route 0.70 % <0.7 % Urinary excretion; Unchanged drug; DRUGBANK
Eliminate Route 1.0 % <1 % Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 55.0 % 55 % Optical rotation R; DRUGBANK
Protein Binding 66.0 % 66 % Optical rotation S; DRUGBANK

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 400.0 mg/day 400 mg/day PO, oral Thalomid thalidomide PDR
Max dose for adolescents 400.0 mg/day 400 mg/day PO, oral Thalomid thalidomide PDR
Max dose for adults 400.0 mg/day 400 mg/day PO, oral Thalomid thalidomide PDR
Max dose for adults 200.0 mg/day 200 mg/day PO, oral Thalomid thalidomide PDR
Max dose for geriatric 400.0 mg/day 400 mg/day PO, oral Thalomid thalidomide PDR
Max dose for geriatric 200.0 mg/day 200 mg/day PO, oral Thalomid thalidomide PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1